Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE versus POTASSIUM CHLORIDE 0 3 IN DEXTROSE 5 AND SODIUM CHLORIDE 0 2 IN PLASTIC CONTAINER.
Head-to-head clinical analysis: MAGNESIUM SULFATE versus POTASSIUM CHLORIDE 0 3 IN DEXTROSE 5 AND SODIUM CHLORIDE 0 2 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE vs POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
Potassium chloride dissociates to provide potassium ions, which are essential for maintaining intracellular fluid volume, acid-base balance, and nerve impulse transmission. Dextrose provides caloric supplementation and sodium chloride maintains extracellular fluid volume and electrolyte balance. The combination corrects electrolyte and fluid deficits.
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
Intravenous infusion; dose depends on serum potassium levels and body weight. Typical adult maintenance: 10-20 mEq/hour, not exceeding 40 mEq/hour or 200 mEq/day. Concentration used: 0.3% potassium chloride (40 mEq/L) in D5 0.2% NaCl.
None Documented
None Documented
Clinical Note
moderateMagnesium sulfate + Gatifloxacin
"The serum concentration of Gatifloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Rosoxacin
"The serum concentration of Rosoxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Levofloxacin
"The serum concentration of Levofloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateTerminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
Potassium: 2-4 hours (plasma, no true terminal t½ due to rapid equilibration with intracellular stores); clinical context: half-life prolonged in renal impairment.
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Renal: potassium >90% excreted in urine (glomerular filtration, distal tubular secretion); chloride 95% renally; dextrose nearly completely reabsorbed; sodium >99% renally with reabsorption.
Category C
Category A/B
Electrolyte
Electrolyte
Magnesium sulfate + Trovafloxacin
"The serum concentration of Trovafloxacin can be decreased when it is combined with Magnesium sulfate."